Background
psoriasis
NAIL PSORIASIS, PSORIASIS
Nail psoriasis is a common, physiologically, and psychologically disruptive, and yet often under-treated manifestation of psoriasis [The phase III VOYAGE 1 and 2 clinical trials in patients with psoriasis found that treatment with the anti-interleukin (IL)-23 monoclonal antibody, guselkumab, resulted in a greater proportion of patients achieving nail efficacy endpoints than placebo (to week 16) and a similar proportion to adalimumab (to week 24) [This 